Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer in Combination With Pembrolizumab as First-Line Treatment

NCT07353957 is registered in ClinicalTrials.gov with Merus B.V. as lead sponsor.

NCT NCT07353957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07353957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer in Combination With Pembrolizumab as First-Line Treatment
Lead sponsor
Merus B.V.
Phase
Phase 2
Overall status
Withdrawn
Start date
March 27, 2026
Completion date
February 27, 2031
Enrollment
0 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer - non small cell non-squamous, lung cancer - non small cell squamous